Senseonics (NYSE:SENS) said this week that it won another FDA approval for its implantable continuous glucose monitoring system, giving nurse practitioners and physicians assistants the ability to implant and remove the Eversense device.
When the product was first approved by the FDA in June, only trained physicians were allowed to conduct the sensor insertion and removal procedures.
Get the full story at our sister site, Drug Delivery Business News.
The post Senseonics wins another FDA approval for its implantable CGM appeared first on MassDevice.
from MassDevice https://ift.tt/2yVwQdO
Cap comentari:
Publica un comentari a l'entrada